Abstract
Objective To investigate the clinical effect of large-dose daunorubicin as induction therapy on acute myeloid leukemia(AML).Methods Thirty-seven patients who were diagnosed as AML received either the standard dose (21 cases,45 mg per square meter of body-surface area) or a large dose (16 cases,60 mg per square meter) combined with seven daily doses of cytarabine (100 mg per square meter) by continuous intravenous infusion.The clinical effect and adverse events were observed.Results Large-dose daunorubicin,as compared with a standard dose of the drug,resulted in a similar rate of complete remission (75％ vs 71.4％,P ＞0.05).The rates of serious adverse events were similar in the two groups,but the neutrophils counts in high dose daunorubicin group were lower than those in standard dose daunorubincin group (P ＜ 0.05).Conclusions The efficacy of large dose daunorubicin is close to that of standard dose daunorubicin in induction therapy for adult AML.The rates of serious adverse events were similar in the two groups. Key words: Acute myelocytic leukemia ; Daunorubicin ; Cytarabine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
